8-K: Cognition Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Cognition Therapeutics announces its Q1 2025 financial results, highlighting progress in its Alzheimer's disease and dementia with Lewy bodies (DLB) programs, including an FDA meeting request and upcoming presentation of Phase 2 results.

Summary

• Cognition Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• The company requested an end-of-Phase 2 (EOP2) meeting with the FDA to review results from the SHINE study in Alzheimer's disease.
• They are also initiating the process of securing a commercial investigational new drug (IND) application for zervimesine (CT1812) in DLB to request a separate EOP2 meeting.
• Phase 2 SHIMMER study results in DLB were accepted for presentation at the Alzheimers Association International Congress (AAIC) in July 2025.
• The company presented two posters at the Association for Research in Vision and Ophthalmology (ARVO) meeting describing zervimesine's role in regulating lipid metabolism and protecting retinal cells.
• Cash and cash equivalents as of March 31, 2025, were approximately $16.4 million, with $47.0 million in obligated grant funds remaining.
• The company estimates sufficient cash to fund operations and capital expenditures into the fourth quarter of 2025.
• Research and development expenses were $10.8 million for the quarter, compared to $10.6 million in 2024.
• General and administrative expenses were $3.0 million, compared to $3.5 million in 2024.
• The company reported a net loss of $8.5 million, or $(0.14) per share, compared to a net loss of $9.2 million, or $(0.27) per share, in the same period in 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is progress in clinical trials and regulatory engagement, the limited cash runway and net loss temper the positive aspects.

Positives

• The company is actively engaging with the FDA regarding its Alzheimer's and DLB programs.
• The SHIMMER study results in DLB being accepted for presentation at AAIC is a positive development.
• The company has secured significant grant funding from the National Institute of Aging.
• The company is actively presenting research at scientific conferences.

Negatives

• The company reported a net loss of $8.5 million for the first quarter of 2025.
• The company's cash runway is only estimated to last into the fourth quarter of 2025, raising concerns about future funding needs.

Risks

• The company's cash runway is limited, potentially requiring additional funding in the near future.
• Clinical trial results may not be favorable, impacting the company's development programs.
• Regulatory approvals are not guaranteed and are subject to change.
• Competition in the neurodegenerative disease space is intense.

Future Outlook

The company anticipates its current cash reserves and grant funding will be sufficient to fund operations into the fourth quarter of 2025. They plan to continue advancing their Alzheimer's disease and DLB programs, including seeking regulatory feedback and presenting clinical trial results.

Management Comments

• During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimers disease and dementia with Lewy bodies (DLB) programs, stated Lisa Ricciardi, Cognitions president and CEO.

Industry Context

Cognition Therapeutics is operating in the competitive field of neurodegenerative disease therapeutics, focusing on Alzheimer's disease and DLB. The company's approach of targeting the sigma-2 receptor is distinct from other approaches in the field. The company's progress is being closely watched by investors and competitors alike.

Comparison to Industry Standards

• Biogen and Eisai's Lecanemab (Leqembi) is an approved Alzheimer's drug that targets amyloid plaques, while Cognition's zervimesine targets sigma-2 receptors, representing a different mechanism of action.
• Other companies like AC Immune and Roche are also developing Alzheimer's therapies, creating a competitive landscape.
• The $16.4 million in cash and cash equivalents is relatively low compared to larger pharmaceutical companies, potentially limiting Cognition's ability to fund extensive clinical trials without additional funding.

Stakeholder Impact

• Shareholders may be concerned about the limited cash runway and potential need for future capital raises.
• Patients with Alzheimer's disease and DLB may benefit from the company's clinical development programs if successful.
• Employees' job security could be affected by the company's financial performance and ability to secure funding.

Next Steps

• The company will pursue an end-of-Phase 2 (EOP2) meeting with the FDA for the SHINE study in Alzheimer's disease.
• The company will secure a commercial investigational new drug (IND) application for zervimesine (CT1812) in DLB and request a separate EOP2 meeting.
• The company will present Phase 2 SHIMMER study results in DLB at the Alzheimers Association International Congress (AAIC) in July 2025.
• The company will continue to advance its clinical programs in dementia with Lewy bodies (DLB) and Alzheimers disease.

Key Dates

Keywords

Cognition Therapeutics, Zervimesine, Alzheimer's disease, Dementia with Lewy bodies, DLB, Clinical trials, Financial results, FDA, SHINE study, SHIMMER study, Neurodegenerative disorders